483 related articles for article (PubMed ID: 27890175)
1. Malignancy and Janus Kinase Inhibition.
Sivaraman P; Cohen SB
Rheum Dis Clin North Am; 2017 Feb; 43(1):79-93. PubMed ID: 27890175
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
[TBL] [Abstract][Full Text] [Related]
3. [JAK inhibitor].
Yamaoka K; Tanaka Y
Nihon Rinsho; 2013 Jul; 71(7):1243-7. PubMed ID: 23961674
[TBL] [Abstract][Full Text] [Related]
4. Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme.
Curtis JR; Lee EB; Martin G; Mariette X; Terry KK; Chen Y; Geier J; Andrews J; Kaur M; Fan H; Nduaka CI
Clin Exp Rheumatol; 2017; 35(4):614-622. PubMed ID: 28240592
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Vyas D; O'Dell KM; Bandy JL; Boyce EG
Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
Yamaoka K; Tanaka Y
Expert Opin Pharmacother; 2014 Jan; 15(1):103-13. PubMed ID: 24188100
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib for treatment of rheumatoid arthritis.
Rakieh C; Conaghan PG
Adv Ther; 2013 Aug; 30(8):713-26. PubMed ID: 23943546
[TBL] [Abstract][Full Text] [Related]
9. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
Sonomoto K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):443-7. PubMed ID: 27118331
[TBL] [Abstract][Full Text] [Related]
10. Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.
Yamaoka K
Drug Saf; 2016 Sep; 39(9):823-40. PubMed ID: 27193610
[TBL] [Abstract][Full Text] [Related]
11. Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
Curtis JR; Zhang R; Krishnaswami S; Anisfeld A; Chen Y; Strengholt S; Chen C; Geier J
Clin Rheumatol; 2017 Mar; 36(3):683-688. PubMed ID: 27470086
[TBL] [Abstract][Full Text] [Related]
12. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.
MacFarlane LA; Todd DJ
Int J Rheum Dis; 2014 May; 17(4):359-68. PubMed ID: 24460872
[TBL] [Abstract][Full Text] [Related]
13. Promising new treatments for rheumatoid arthritis - the kinase inhibitors.
Yazici Y; Regens AL
Bull NYU Hosp Jt Dis; 2011; 69(3):233-7. PubMed ID: 22035435
[TBL] [Abstract][Full Text] [Related]
14. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
Nakayamada S; Kubo S; Iwata S; Tanaka Y
BioDrugs; 2016 Oct; 30(5):407-419. PubMed ID: 27577235
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
Tanaka Y; Yamaoka K
Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
Kawalec P; Mikrut A; Wiśniewska N; Pilc A
Clin Rheumatol; 2013 Oct; 32(10):1415-24. PubMed ID: 23877486
[TBL] [Abstract][Full Text] [Related]
17. [A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].
Varisco PA; So A
Rev Med Suisse; 2014 Jan; 10(414):187-91. PubMed ID: 24624736
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib in the treatment of active rheumatoid arthritis in adults.
Fleischmann R
Immunotherapy; 2018 Jan; 10(1):39-56. PubMed ID: 29043892
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
Charles-Schoeman C; Wicker P; Gonzalez-Gay MA; Boy M; Zuckerman A; Soma K; Geier J; Kwok K; Riese R
Semin Arthritis Rheum; 2016 Dec; 46(3):261-271. PubMed ID: 27443588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]